Boothbay Fund Management Increases Stake in Regeneron Pharmaceuticals

Biotech firm's shares rise as investment firm boosts ownership

Mar. 17, 2026 at 7:24am

Got story updates? Submit your updates here. ›

Boothbay Fund Management LLC has increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 57.1% during the third quarter, according to a recent SEC filing. The investment firm now owns 4,240 shares of the biopharmaceutical company's stock, valued at $2.38 million.

Why it matters

Regeneron is a leading biotech firm known for its innovative drug discovery technologies and pipeline of biologic therapies. Increased investment from institutional investors like Boothbay Fund Management signals confidence in the company's long-term growth prospects.

The details

Boothbay Fund Management added 1,541 shares of Regeneron to its portfolio during the third quarter. The firm now owns a total of 4,240 shares of the biopharmaceutical company's stock. Regeneron's shares have seen strong performance, rising over 60% in the past year as the company has advanced its drug pipeline and navigated the COVID-19 pandemic.

  • Boothbay Fund Management increased its Regeneron stake during the 3rd quarter of 2025.
  • Regeneron's shares have risen over 60% in the past 12 months.

The players

Boothbay Fund Management LLC

An investment management firm that focuses on alternative strategies and manages over $1 billion in assets.

Regeneron Pharmaceuticals, Inc.

A leading biotechnology company known for its innovative drug discovery technologies and pipeline of biologic therapies.

Got photos? Submit your photos here. ›

The takeaway

Regeneron's continued growth and innovation in the biotech space has attracted increased investment from institutional investors like Boothbay Fund Management, signaling confidence in the company's long-term prospects.